• Info
  • Insider Ownership

Insider Trading & Ownership of Ali Behbahani

Location
Menlo Park, CA
Summary
The estimated net worth of Ali Behbahani is at least $169M dollars as of 15 Dec 2025. Ali Behbahani is the 10%+ Owner of Savara Inc and owns shares of Savara Inc (SVRA) stock worth about $109M. Ali Behbahani is the 10%+ Owner of MBX Biosciences, Inc. and owns shares of MBX Biosciences, Inc. (MBX) stock worth about $38.6M. Ali Behbahani is the Director of Black Diamond Therapeutics, Inc. and owns shares of Black Diamond Therapeutics, Inc. (BDTX) stock worth about $17.9M. Ali Behbahani is the 10%+ Owner of Trevi Therapeutics, Inc. and owns shares of Trevi Therapeutics, Inc. (TRVI) stock worth about $1.92M. Ali Behbahani is the 10%+ Owner of Metacrine, Inc. and owns shares of Metacrine, Inc. stock worth about $1.2M. Ali Behbahani is the Director of Arcellx, Inc. and owns shares of Arcellx, Inc. (ACLX) stock worth about $304K. Ali Behbahani is the Director of CVRx, Inc. and owns shares of CVRx, Inc. (CVRX) stock worth about $146K. Ali Behbahani is the Director of MINERVA SURGICAL INC and owns shares of MINERVA SURGICAL INC stock worth about $11.9K. Ali Behbahani is the 10%+ Owner of Mirum Pharmaceuticals, Inc. and owns shares of Mirum Pharmaceuticals, Inc. (MIRM) stock worth about $3.79K.
Signature
/s/ Zachary Bambach, attorney-in-fact
All Insider Reports
All Insider Reports

Notify me when Ali Behbahani files a new Insider Trading report.

⭐ Subscribe ⭐

Ownership of Ali Behbahani

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
SVRA Savara Inc 10%+ Owner $109M 17 Jul 2023
MBX MBX Biosciences, Inc. 10%+ Owner $38.6M 16 Sep 2024
BDTX Black Diamond Therapeutics, Inc. Director $17.9M 12 Dec 2025
TRVI Trevi Therapeutics, Inc. 10%+ Owner $1.92M 11 Apr 2022
MTCR Metacrine, Inc. 10%+ Owner $1.2M 10 Dec 2021
ACLX Arcellx, Inc. Director $304K 12 Aug 2025
CVRX CVRx, Inc. Director $146K 04 Jun 2024
UTRS MINERVA SURGICAL INC Director $11.9K 10 Jun 2022
MIRM Mirum Pharmaceuticals, Inc. 10%+ Owner $3.79K 13 Jun 2023
ADAP Adaptimmune Therapeutics PLC Director $0 15 Aug 2025
NEUE NeueHealth, Inc. Director, 10%+ Owner $0 -$26.4K -100% 02 Oct 2025
AKUS Akouos, Inc. 10%+ Owner 30 Nov 2022
CRSP CRISPR Therapeutics AG Director 05 Jun 2025
GNCA GENOCEA BIOSCIENCES, INC. Director, 10%+ Owner 24 May 2022
KRRO Korro Bio, Inc. Director, 10%+ Owner 11 Jun 2025
GLUE Monte Rosa Therapeutics, Inc. Director, 10%+ Owner 13 Jun 2025
NKTX Nkarta, Inc. Director 05 Jun 2025
OYST Oyster Point Pharma, Inc. Director 03 Jan 2023

Insider Transactions Reported by Ali Behbahani:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.